This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Biological therapies for rheumatoid arthritis

Authoring team

Biologic therapies are used where intensive treatment with DMARDs (such as methotrexate, hydroxychloroquine, leflunomide and sulfasalazine) has not suppressed rheumatoid arthritis satisfactorily. They may be given in combination with DMARDs, and include ;

  • Anti-tumour necrosis factor (anti-TNF) agents - such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab.
  • Other biological agents, including abatacept, sarilumab and tocilizumab.
  • Targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) such as Janus kinase (Jak) inhibitors (e.g. tofacitinib and baricitinib).

Reference

  1. NICE. Rheumatoid arthritis in adults: management. NICE guideline NG100. Published July 2018, last updated October 2020

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.